215 results on '"Liu H"'
Search Results
2. Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance
3. Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer
4. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
5. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014
6. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas
7. 180O Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study
8. 17P Clinical, pathological complete response and prognosis characteristics of HER2-low breast cancer in neoadjuvant chemotherapy setting: A retrospective analysis
9. 190P Real-world applications of poly (ADP-ribose) polymerase inhibitors for ovarian cancer: A single-center study in China
10. 422P Molecular mechanism in prostate cancer with TP53 mutation
11. 1175P Pharmacokinetics of ensartinib in advanced solid tumors and anaplastic lymphoma kinase-positive non-small cell lung cancer
12. 618O A phase I study of TRS005: An anti-CD20-MMAE antibody-drug conjugate, in relapsed or refractory b cell non-Hodgkin lymphoma
13. 558P Molecular subtyping endometrial carcinoma in Chinese population applying an NGS-based classifier and its association with prognosis
14. 1417P Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review
15. Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy
16. Power and limits of modern cancer diagnostics: cancer of unknown primary
17. P-172 A multi-center, open-label, randomized controlled trial of nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer (PC)
18. VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)
19. 144P Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer (TD-NICE): A single arm, phase II study
20. 151P CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with doublet chemotherapy (Nab-PTX & S-1) and apatinib (anti-angiogenic TKI) for the first-line treatment of stage IV gastric cancer (GC)
21. 514MO The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC).
22. 309P A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (EBC) in China: Interim analysis of the NER-Tree study.
23. Second cancers after testicular cancer diagnosed after 1980 in Sweden
24. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
25. 100P Characteristics and outcomes of patients (pts) with NTRK fusion-positive (NTRK+) metastatic / locally advanced (LA) solid tumours receiving non-TRK inhibitor (TRKi) standard of care (SoC), and prognostic value of NTRK fusions in clinical practice
26. 666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A
27. 1300P A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
28. 830MO Integrated driver mutations profile of Chinese NK/T cell lymphoma
29. 138P Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)
30. 300P Mutational patterns across breast cancer subtypes during metastatic disease progression
31. 1187P A mutation characteristics analysis of SMARCA4defSMARCA2wt in lung cancer
32. 828MO Exonic mutation profile of primary gastrointestinal diffuse large B-cell lymphoma
33. 1180P Anlotinib combined with radiotherapy in locally advanced non-small cell lung cancer (LANSCLC): A prospective, single-arm, phase II study
34. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study
35. 662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B
36. 831MO Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial
37. 1057P ROS1 mutation can serve- as a potential efficacious predictor of immunotherapy in melanoma patients
38. 1336P Anlotinib in elderly patients with advanced non-squamous non-small cell lung cancer (NSCLC) who had not received systemic chemotherapy: A single-arm, multi-center, phase II study
39. 1403P Toripalimab combined with nab-paclitaxel/docetaxel as second-line treatment in patients with advanced gastric cancer: Preliminary results from a single-arm, open-label phase II trial
40. 840P Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
41. 2036P Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
42. 431P Distribution and prognostic role of HER2 status of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in HER2- metastatic breast cancer (MBC) patients (pts)
43. LBA58 Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial
44. 1013TiP Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
45. 1144P High-plex spatial profiling of cutaneous squamous cell carcinoma to identify biomarkers associated with clinical outcomes: The cMIC study
46. 1044P A phase Ia first-in-human study of JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors
47. 744MO AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)
48. 499O A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway-activated
49. 3O IGSF8 is an innate immune checkpoint and cancer immunotherapy target
50. 1567P The effect of SGLT2i and DPP4i on new-onset gastric cancer and gastric diseases in type 2 diabetes mellitus: A population-based cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.